|
|
Volumn 16 Suppl 2, Issue , 2011, Pages 45-50
|
|
Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA INTERFERON;
ANGIOGENESIS INHIBITOR;
INTERLEUKIN 2;
TARGET OF RAPAMYCIN KINASE;
CLINICAL TRIAL (TOPIC);
EUROPE;
EVIDENCE BASED MEDICINE;
HUMAN;
KIDNEY CARCINOMA;
KIDNEY TUMOR;
METHODOLOGY;
MOLECULARLY TARGETED THERAPY;
PRACTICE GUIDELINE;
REVIEW;
UNITED STATES;
ANGIOGENESIS INHIBITORS;
CARCINOMA, RENAL CELL;
CLINICAL TRIALS AS TOPIC;
EUROPE;
EVIDENCE-BASED MEDICINE;
HUMANS;
INTERFERON-ALPHA;
INTERLEUKIN-2;
KIDNEY NEOPLASMS;
MOLECULAR TARGETED THERAPY;
PRACTICE GUIDELINES AS TOPIC;
TOR SERINE-THREONINE KINASES;
UNITED STATES;
|
|
EID: 79955850541
PISSN: None
EISSN: 1549490X
Source Type: Journal
DOI: 10.1634/theoncologist.2011-S2-45 Document Type: Review |
|
Times cited : (71)
|
|
References (0)
|
